Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects

Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):121-7. doi: 10.1016/j.numecd.2005.05.006. Epub 2005 Oct 20.

Abstract

Background and aim: Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries. The aim of this study was to assess the effects and the advantages of a combined dietary supplementation with PUFA n-3, vitamin E, niacin and gamma-oryzanol on lipid profile, inflammatory status and oxidative balance.

Methods and results: Fifty-seven dyslipidemic volunteers were randomly assigned to receive: placebo (group A, 19 subjects); PUFA n-3 and vitamin E (group B, 18 subjects); the same as B plus gamma-oryzanol and niacin (group C, 20 subjects). Lipid profile, reactive oxygen species (ROS), total antioxidant capacity (TAC), vitamin E, interleukin 1-beta (IL1-beta), tumor necrosis factor (TNF-alpha) and thromboxane B2 (TXB2) were determined at baseline (T0) and after four months (T1). All dyslipidemic subjects showed, at baseline, oxidative stress and, after four months, all biochemical markers improved significantly in groups treated with dietary supplementation. Particularly in group C all lipid patterns improved significantly.

Conclusions: Our findings demonstrate that the strategy of combining different compounds, which protect each other and act together at different levels of the lipid chain production, improves lipid profile, inflammatory and oxidative status, allowing us to reduce the dose of each compound under the threshold of its side effects.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antioxidants / administration & dosage
  • Antioxidants / therapeutic use*
  • Atherosclerosis / epidemiology
  • Atherosclerosis / etiology
  • Cytokines / metabolism
  • Dietary Supplements
  • Drug Therapy, Combination
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / therapeutic use
  • Female
  • Humans
  • Hyperlipidemias / complications
  • Hyperlipidemias / drug therapy*
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / therapeutic use*
  • Inflammation Mediators / metabolism
  • Lipid Metabolism / drug effects*
  • Male
  • Middle Aged
  • Niacin / administration & dosage
  • Niacin / therapeutic use
  • Oxidation-Reduction
  • Oxidative Stress / drug effects*
  • Phenylpropionates / administration & dosage
  • Phenylpropionates / therapeutic use
  • Reactive Oxygen Species / metabolism
  • Risk Factors
  • Vitamin E / administration & dosage
  • Vitamin E / therapeutic use

Substances

  • Antioxidants
  • Cytokines
  • Fatty Acids, Omega-3
  • Hypolipidemic Agents
  • Inflammation Mediators
  • Phenylpropionates
  • Reactive Oxygen Species
  • Vitamin E
  • Niacin
  • gamma-oryzanol